Show simple item record

dc.contributor.authorBoia, Raquel
dc.contributor.authorRuzafa Andrés, Noelia ORCID
dc.contributor.authorAires, Inês Dinis
dc.contributor.authorPereiro Díez, Xandra ORCID
dc.contributor.authorAmbrósio, António Francisco
dc.contributor.authorVecino Cordero, Elena ORCID
dc.contributor.authorSantiago, Ana Raquel
dc.date.accessioned2020-05-05T14:59:09Z
dc.date.available2020-05-05T14:59:09Z
dc.date.issued2020-03-25
dc.identifier.citationInternational Journal of Molecular Sciences 21(7) : (2020) // Article ID 2262es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/43016
dc.description.abstractThe retinal ganglion cells (RGCs) are the output cells of the retina into the brain. In mammals, these cells are not able to regenerate their axons after optic nerve injury, leaving the patients with optic neuropathies with permanent visual loss. An effective RGCs-directed therapy could provide a beneficial effect to prevent the progression of the disease. Axonal injury leads to the functional loss of RGCs and subsequently induces neuronal death, and axonal regeneration would be essential to restore the neuronal connectivity, and to reestablish the function of the visual system. The manipulation of several intrinsic and extrinsic factors has been proposed in order to stimulate axonal regeneration and functional repairing of axonal connections in the visual pathway. However, there is a missing point in the process since, until now, there is no therapeutic strategy directed to promote axonal regeneration of RGCs as a therapeutic approach for optic neuropathies.es_ES
dc.description.sponsorshipThis work was supported by Foundation for Science and Technology (FCT), Portugal (Fellowships PD/BD/114115/2015 and PD/BD/127821/2016, Grant PTDC/NEU-OSD/3123/2014 and Strategic Projects UID/NEU/04539/2013, UID/NEU/04539/2019, UIDP/04539/2020 and UIDB/04539/2020), FEDER-COMPETE POCI-01-0145-FEDER-016849, FCOMP-01-0124-FEDER-028417, POCI-01-0145-FEDER-007440) and Centro 2020 Regional Operational Programme (CENTRO-01-0145-FEDER-000008: BrainHealth 2020). Grupos UPV/EHU GIU18/50, PUE 2018-04 and ELKARTEK KK-2019/00086 to E.V.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectretinal ganglion cellses_ES
dc.subjectneurodegenerationes_ES
dc.subjectaxonal regenerationes_ES
dc.subjectneuroprotectiones_ES
dc.subjectoptic neuropathieses_ES
dc.titleNeuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Aheades_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2020-04-15T13:19:26Z
dc.rights.holder© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/21/7/2262es_ES
dc.identifier.doi10.3390/ijms21072262
dc.departamentoesBiología celular e histología
dc.departamentoeuZelulen biologia eta histologia


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).